Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Acquired by Edgestream Partners L.P.

Edgestream Partners L.P. increased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 116.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 86,001 shares of the biopharmaceutical company's stock after acquiring an additional 46,352 shares during the period. Edgestream Partners L.P. owned approximately 0.07% of Halozyme Therapeutics worth $4,923,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of HALO. Verdence Capital Advisors LLC increased its holdings in shares of Halozyme Therapeutics by 1.9% during the third quarter. Verdence Capital Advisors LLC now owns 13,232 shares of the biopharmaceutical company's stock valued at $757,000 after acquiring an additional 252 shares in the last quarter. GAMMA Investing LLC increased its stake in Halozyme Therapeutics by 96.6% during the 2nd quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 254 shares in the last quarter. Fifth Third Bancorp raised its holdings in Halozyme Therapeutics by 2.4% in the second quarter. Fifth Third Bancorp now owns 11,206 shares of the biopharmaceutical company's stock worth $587,000 after buying an additional 261 shares during the last quarter. Private Advisor Group LLC lifted its stake in shares of Halozyme Therapeutics by 1.8% in the second quarter. Private Advisor Group LLC now owns 22,753 shares of the biopharmaceutical company's stock worth $1,191,000 after buying an additional 412 shares in the last quarter. Finally, Juncture Wealth Strategies LLC grew its holdings in shares of Halozyme Therapeutics by 3.6% during the third quarter. Juncture Wealth Strategies LLC now owns 12,058 shares of the biopharmaceutical company's stock valued at $690,000 after buying an additional 415 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. TD Cowen boosted their price objective on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the stock a "buy" rating in a report on Wednesday, August 7th. Piper Sandler boosted their price target on Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a "neutral" rating in a research note on Monday, November 4th. Wells Fargo & Company cut Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and increased their price objective for the company from $58.00 to $62.00 in a research report on Monday, October 7th. JPMorgan Chase & Co. lowered Halozyme Therapeutics from an "overweight" rating to a "neutral" rating and boosted their target price for the stock from $52.00 to $57.00 in a research report on Thursday, September 19th. Finally, Cowen restated a "buy" rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $61.11.

Insider Transactions at Halozyme Therapeutics

In related news, CEO Helen Torley sold 10,000 shares of the company's stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $59.09, for a total transaction of $590,900.00. Following the completion of the sale, the chief executive officer now directly owns 676,744 shares in the company, valued at $39,988,802.96. This represents a 1.46 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. In the last quarter, insiders sold 60,000 shares of company stock valued at $3,425,000. Company insiders own 2.40% of the company's stock.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ:HALO traded down $0.27 during mid-day trading on Friday, reaching $48.20. 720,988 shares of the company traded hands, compared to its average volume of 2,359,745. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. The firm has a market cap of $6.13 billion, a PE ratio of 15.96, a PEG ratio of 0.44 and a beta of 1.29. The company's 50 day moving average price is $53.28 and its 200-day moving average price is $53.79. Halozyme Therapeutics, Inc. has a 52 week low of $33.15 and a 52 week high of $65.53.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.